Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albumin-bound paclitaxel plus camrelizumab for advanced or metastatic urothelial carcinoma
ChiCTR2000033820Phase 2Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Jul 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel and camrelizumab in transitional cell carcinoma (TCC), sponsored by Sun Yat-sen University Cancer Center. Primary endpoints: Progression-free survival and Objective response rate. Started Jul 2020; status: recruiting.
02
Drugs
paclitaxelcamrelizumab
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on ChiCTR2000033820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000033820.